Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar

Detalhes bibliográficos
Ano de defesa: 2021
Autor(a) principal: Silva, Luisa Berlato lattes
Orientador(a): Danesi, Cristiane Cademartori lattes
Banca de defesa: Barin, Luisa lattes, Marinho, Roberto lattes
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Santa Maria
Centro de Ciências da Saúde
Programa de Pós-Graduação: Programa de Pós-Graduação em Ciências Odontológicas
Departamento: Odontologia
País: Brasil
Palavras-chave em Português:
Palavras-chave em Inglês:
Área do conhecimento CNPq:
Link de acesso: http://repositorio.ufsm.br/handle/1/21150
Resumo: Osteonecrosis is a bone pathology, with a still unknown etiopathogenesis, which was first reported in 2003 by Marx. In 2014 the Association of Oral and Maxillofacial Surgeons (AAOMS) described the concept of osteonecrosis, as an area of bone exposure in the jaw or jaw that does not repair in eight weeks due to a temporary or permanent loss of blood supply at the site. It affects, in most cases, patients who chronically use antiresorptive drugs and some associated factors such as corticosteroid therapy, diabetes mellitus, tooth extraction and other invasive dental procedures. Recent work investigates in rats the osteonecrosis induced by these drugs, such as alendronate (AL), zoledronic acid (Z) and denosumab (Dmab), in order to clarify the etiopathogenesis, as well as to study means of prevention and treatment of the disease. the aim of this study was to compare antiresorptive drugs in an animal model in MRONJ rats, using three different antiresorptive drugs: alendronate, zoledronic acid and denosumab, one for each experimental group, based on the clinical and histological parameters of the region undergoing extraction. The clinical parameters evaluated were: area of bone exposure, fistula, poor healing of soft tissue and inflammation in the alveolus. The histological parameters included the analysis of bone necrosis, inflammatory infiltrate (qualitative and quantitative analysis), blood vessels (quantitative analysis), bone sequestration and root rest. There were 35 male Wistar rats, randomized into 6 groups: Negative Control Group (CN) physiological saline therapy: GNZ (n = 6), GNAL (n = 6), GNDmab (n = 5); Alendronate Group (GAL) therapy with AL (n = 6); Zometa Group (GZ) Z therapy (n = 6); Denosumab Group (GDmab) Dmab therapy (n = 6). The dose applied to each animal will be according to its weekly weight, following the ratio: GAL 1 mg / Kg - subcutaneous, GZ 0.06mg / kgintraperitoneal and GDmab 0.25mg / kg - intraperitoneal. The GAL group was submitted to 8 applications of LA for a period of 8 weeks (1 weekly application), when completing the eighth week the rats were submitted to tooth extraction. And after 28 days of tooth extraction, they were euthanized, along with 6 rats from the GNAL group. The medication was maintained, once a week, until euthanasia (thirteenth week) for the GAL group. The GZ group received Z four times a week, for four weeks, when the fourth week was completed, tooth extraction was performed, after which the 28-day period was awaited for the euthanasia of the animals in the respective group and another 6 in the GNZ group. The GDmab group received a total of 8 applications of Dmab, for a period of 4 weeks (2 weekly applications), when the fourth week was completed, the animals in the group underwent dental extraction and after 28 days were euthanized, together with the 6 remaining rats from the GNDmab group. The statistical analysis for qualitative variables was used Fisher's exact test, and for the analysis of quantitative variables, One-way ANOVA with Tukey's post hoc was used. Considering a significance level of 0.05. Our results demonstrated a higher prevalence of histological osteonecrosis in the group in the BFs when compared to the Denosumab group, as well as the decrease in the number of vessels was more frequent in the groups of the BFs. Thus, we conclude that, due to the decrease in angiogenesis and the increase in MRONJ in bone tissue, bisphosphonates have a greater alteration in the bone mechan
id UFSM-20_d6333bb6f705fd6514fa3bd19e89b537
oai_identifier_str oai:repositorio.ufsm.br:1/21150
network_acronym_str UFSM-20
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling 2021-06-18T17:31:47Z2021-06-18T17:31:47Z2021-01-14http://repositorio.ufsm.br/handle/1/21150Osteonecrosis is a bone pathology, with a still unknown etiopathogenesis, which was first reported in 2003 by Marx. In 2014 the Association of Oral and Maxillofacial Surgeons (AAOMS) described the concept of osteonecrosis, as an area of bone exposure in the jaw or jaw that does not repair in eight weeks due to a temporary or permanent loss of blood supply at the site. It affects, in most cases, patients who chronically use antiresorptive drugs and some associated factors such as corticosteroid therapy, diabetes mellitus, tooth extraction and other invasive dental procedures. Recent work investigates in rats the osteonecrosis induced by these drugs, such as alendronate (AL), zoledronic acid (Z) and denosumab (Dmab), in order to clarify the etiopathogenesis, as well as to study means of prevention and treatment of the disease. the aim of this study was to compare antiresorptive drugs in an animal model in MRONJ rats, using three different antiresorptive drugs: alendronate, zoledronic acid and denosumab, one for each experimental group, based on the clinical and histological parameters of the region undergoing extraction. The clinical parameters evaluated were: area of bone exposure, fistula, poor healing of soft tissue and inflammation in the alveolus. The histological parameters included the analysis of bone necrosis, inflammatory infiltrate (qualitative and quantitative analysis), blood vessels (quantitative analysis), bone sequestration and root rest. There were 35 male Wistar rats, randomized into 6 groups: Negative Control Group (CN) physiological saline therapy: GNZ (n = 6), GNAL (n = 6), GNDmab (n = 5); Alendronate Group (GAL) therapy with AL (n = 6); Zometa Group (GZ) Z therapy (n = 6); Denosumab Group (GDmab) Dmab therapy (n = 6). The dose applied to each animal will be according to its weekly weight, following the ratio: GAL 1 mg / Kg - subcutaneous, GZ 0.06mg / kgintraperitoneal and GDmab 0.25mg / kg - intraperitoneal. The GAL group was submitted to 8 applications of LA for a period of 8 weeks (1 weekly application), when completing the eighth week the rats were submitted to tooth extraction. And after 28 days of tooth extraction, they were euthanized, along with 6 rats from the GNAL group. The medication was maintained, once a week, until euthanasia (thirteenth week) for the GAL group. The GZ group received Z four times a week, for four weeks, when the fourth week was completed, tooth extraction was performed, after which the 28-day period was awaited for the euthanasia of the animals in the respective group and another 6 in the GNZ group. The GDmab group received a total of 8 applications of Dmab, for a period of 4 weeks (2 weekly applications), when the fourth week was completed, the animals in the group underwent dental extraction and after 28 days were euthanized, together with the 6 remaining rats from the GNDmab group. The statistical analysis for qualitative variables was used Fisher's exact test, and for the analysis of quantitative variables, One-way ANOVA with Tukey's post hoc was used. Considering a significance level of 0.05. Our results demonstrated a higher prevalence of histological osteonecrosis in the group in the BFs when compared to the Denosumab group, as well as the decrease in the number of vessels was more frequent in the groups of the BFs. Thus, we conclude that, due to the decrease in angiogenesis and the increase in MRONJ in bone tissue, bisphosphonates have a greater alteration in the bone mechanA osteonecrose é uma patologia óssea, com etiopatogenia ainda desconhecida, que foi relatada pela primeira vez em 2003 por Marx. Em 2014 a Association of Oral and Maxillofacial Surgeons (AAOMS) descreveu o conceito da osteonecrose, como sendo uma área de exposição óssea na maxila ou mandíbula que não repara em oito semanas devido a uma perda temporária ou permanente de suprimento sanguíneo no local. Acomete, na maioria dos casos, pacientes que utilizam, cronicamente, medicamentos antirreabsortivos e alguns fatores associados como corticoterapia, diabetes mellitus, exodontia e demais procedimentos odontológicos invasivos. Trabalhos recentes investigam em ratos a osteonecrose induzida por esses medicamentos como o alendronato (AL), ácido zoledrônico (Z) e o denosumab (Dmab), a fim de, esclarecer a etiopatogenia, assim como, estudar meios de prevenção e tratamento da doença. o objetivo deste estudo foi comparar as drogas antirreabsortivas em um modelo animal em ratos de MRONJ, utilizando três diferentes fármacos antirreabsortivos: alendronato, ácido zoledrônico e denosumab, uma para cada grupo experimental, baseado nos parâmetros clínicos e histológicos da região submetida à exodontia. Os parâmetros clínicos avaliados foram: área de exposição óssea, fístula, má cicatrização de tecido mole e inflamação no alvéolo. Já os parâmetros histológicos compreenderam a análise de necrose óssea, infiltrado inflamatório (análise qualitativa e quantitativa), vasos sanguíneos (análise quantitativa), sequestro ósseo e resto radicular. Foram 35 ratos machos Wistar, randomizados em 6 grupos: Grupo Controle Negativo (CN) terapia com solução salina fisiológica: GNZ (n=6), GNAL (n=6), GNDmab (n=5); Grupo Alendronato (GAL) terapia com AL (n=6); Grupo Zometa (GZ) terapia com Z (n=6); Grupo Denosumab (GDmab) terapia com Dmab (n=6). A dose aplicada em cada animal será de acordo com seu peso semanal, seguindo a relação: GAL 1 mg/Kg – subcutânea, GZ 0,06mg/kg- intraperitoneal e GDmab 0,25mg/kg – intraperitoneal. O grupo GAL foi submetido a 8 aplicações de AL por um período de 8 semanas (1 aplicação semanal), ao completar a oitava semana os ratos foram submetidos a extração dentária. E após 28 dias da extração dentária foram eutanasiados, juntamente com 6 ratos do grupo GNAL. A medicação foi mantida, 1 vez na semana, até a eutanásia (décima terceira semana) para o grupo GAL. O grupo GZ recebeu o Z quatro vezes por semana, por quatro semanas, quando completou a quarta semana foi realizado a extração dentária, posteriormente foi aguardado o período de 28 dias para a realização da eutanásia dos animais do respectivo grupo e mais 6 do grupo GNZ. O grupo GDmab recebeu um total de 8 aplicações de Dmab, por um período de 4 semanas (2 aplicações semanais), quando completou a quarta semana os animais do grupo foram submetidos a extração dentária e depois de 28 dias foram eutanasiados, juntamente com os 6 ratos restantes do grupo GNDmab. A análise estatística para as variáveis qualitativas foi utilizada o teste exato de Fisher, e para a análise das variáveis quantitativas foi utilizado One-way ANOVA com post hoc de Tukey. Considerando um nível de significância de 0,05. Nossos resultados demonstraram uma maior prevalência de osteonecrose histológica no grupo nos BF’s quando comparado ao grupo do Denosumab, bem como a diminuição do número de vasos foi mais frequente nos grupos do BFs. Com isso, concluímos que, pela diminuição da angiogênese e pelo aumento da MRONJ no tecido ósseo, os bisfosfonatos possuem uma maior alteração no mecanismo ósseo.porUniversidade Federal de Santa MariaCentro de Ciências da SaúdePrograma de Pós-Graduação em Ciências OdontológicasUFSMBrasilOdontologiaAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessBisfosfonatosExodontiaDenosumabDisphosphonatesTooth extractionCNPQ::CIENCIAS DA SAUDE::ODONTOLOGIAAvaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistarClinical and histological e evaluation of mandibular osteonecrosis induced by bone modifying agents in wistar ratsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisDanesi, Cristiane Cademartorihttp://lattes.cnpq.br/9106848911495258Ferrazzo, Kivia LinharesXXXXXXXXXXXXXXBarin, LuisaXXXXXXXXXXXXXXXMarinho, RobertoXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSilva, Luisa Berlato400200000000600e4964e40-0663-4dd4-8f14-d62cdf602ede1dc44013-ec57-4497-9b49-ad389c38a33b04b974c8-cef0-437f-afa6-2a447a22eb9a12cdec15-31d1-4e31-89fb-32ab2a72c1ba019bd909-2c54-4eef-9485-76e2f1f9da0breponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSMORIGINALDIS_PPGCO_2021_SILVA_LUISA.pdfDIS_PPGCO_2021_SILVA_LUISA.pdfDissertação de Mestradoapplication/pdf14729909http://repositorio.ufsm.br/bitstream/1/21150/1/DIS_PPGCO_2021_SILVA_LUISA.pdfcf2933f252a2562debb7193d949e1d88MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81956http://repositorio.ufsm.br/bitstream/1/21150/3/license.txt2f0571ecee68693bd5cd3f17c1e075dfMD53CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805http://repositorio.ufsm.br/bitstream/1/21150/2/license_rdf4460e5956bc1d1639be9ae6146a50347MD52TEXTDIS_PPGCO_2021_SILVA_LUISA.pdf.txtDIS_PPGCO_2021_SILVA_LUISA.pdf.txtExtracted texttext/plain98029http://repositorio.ufsm.br/bitstream/1/21150/4/DIS_PPGCO_2021_SILVA_LUISA.pdf.txt0ca0b2bbb30480e3afe9f23f3de2af6bMD54THUMBNAILDIS_PPGCO_2021_SILVA_LUISA.pdf.jpgDIS_PPGCO_2021_SILVA_LUISA.pdf.jpgIM Thumbnailimage/jpeg4278http://repositorio.ufsm.br/bitstream/1/21150/5/DIS_PPGCO_2021_SILVA_LUISA.pdf.jpg3787fbfeb9d638aa33495c4a4676acf5MD551/211502021-06-19 03:00:47.687oai:repositorio.ufsm.br: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ório Institucionalhttp://repositorio.ufsm.br/PUBhttp://repositorio.ufsm.br/oai/requestopendoar:39132021-06-19T06:00:47Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.por.fl_str_mv Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar
dc.title.alternative.eng.fl_str_mv Clinical and histological e evaluation of mandibular osteonecrosis induced by bone modifying agents in wistar rats
title Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar
spellingShingle Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar
Silva, Luisa Berlato
Bisfosfonatos
Exodontia
Denosumab
Disphosphonates
Tooth extraction
CNPQ::CIENCIAS DA SAUDE::ODONTOLOGIA
title_short Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar
title_full Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar
title_fullStr Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar
title_full_unstemmed Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar
title_sort Avaliação clínica e histológica de osteonecrose mandibular induzida por agentes modificadores ósseos em ratos wistar
author Silva, Luisa Berlato
author_facet Silva, Luisa Berlato
author_role author
dc.contributor.advisor1.fl_str_mv Danesi, Cristiane Cademartori
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/9106848911495258
dc.contributor.advisor-co1.fl_str_mv Ferrazzo, Kivia Linhares
dc.contributor.advisor-co1Lattes.fl_str_mv XXXXXXXXXXXXXX
dc.contributor.referee1.fl_str_mv Barin, Luisa
dc.contributor.referee1Lattes.fl_str_mv XXXXXXXXXXXXXXX
dc.contributor.referee2.fl_str_mv Marinho, Roberto
dc.contributor.referee2Lattes.fl_str_mv XXXXXXXXXXXXXX
dc.contributor.authorLattes.fl_str_mv XXXXXXXXXXXXXXXXXXXXXX
dc.contributor.author.fl_str_mv Silva, Luisa Berlato
contributor_str_mv Danesi, Cristiane Cademartori
Ferrazzo, Kivia Linhares
Barin, Luisa
Marinho, Roberto
dc.subject.por.fl_str_mv Bisfosfonatos
Exodontia
Denosumab
topic Bisfosfonatos
Exodontia
Denosumab
Disphosphonates
Tooth extraction
CNPQ::CIENCIAS DA SAUDE::ODONTOLOGIA
dc.subject.eng.fl_str_mv Disphosphonates
Tooth extraction
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS DA SAUDE::ODONTOLOGIA
description Osteonecrosis is a bone pathology, with a still unknown etiopathogenesis, which was first reported in 2003 by Marx. In 2014 the Association of Oral and Maxillofacial Surgeons (AAOMS) described the concept of osteonecrosis, as an area of bone exposure in the jaw or jaw that does not repair in eight weeks due to a temporary or permanent loss of blood supply at the site. It affects, in most cases, patients who chronically use antiresorptive drugs and some associated factors such as corticosteroid therapy, diabetes mellitus, tooth extraction and other invasive dental procedures. Recent work investigates in rats the osteonecrosis induced by these drugs, such as alendronate (AL), zoledronic acid (Z) and denosumab (Dmab), in order to clarify the etiopathogenesis, as well as to study means of prevention and treatment of the disease. the aim of this study was to compare antiresorptive drugs in an animal model in MRONJ rats, using three different antiresorptive drugs: alendronate, zoledronic acid and denosumab, one for each experimental group, based on the clinical and histological parameters of the region undergoing extraction. The clinical parameters evaluated were: area of bone exposure, fistula, poor healing of soft tissue and inflammation in the alveolus. The histological parameters included the analysis of bone necrosis, inflammatory infiltrate (qualitative and quantitative analysis), blood vessels (quantitative analysis), bone sequestration and root rest. There were 35 male Wistar rats, randomized into 6 groups: Negative Control Group (CN) physiological saline therapy: GNZ (n = 6), GNAL (n = 6), GNDmab (n = 5); Alendronate Group (GAL) therapy with AL (n = 6); Zometa Group (GZ) Z therapy (n = 6); Denosumab Group (GDmab) Dmab therapy (n = 6). The dose applied to each animal will be according to its weekly weight, following the ratio: GAL 1 mg / Kg - subcutaneous, GZ 0.06mg / kgintraperitoneal and GDmab 0.25mg / kg - intraperitoneal. The GAL group was submitted to 8 applications of LA for a period of 8 weeks (1 weekly application), when completing the eighth week the rats were submitted to tooth extraction. And after 28 days of tooth extraction, they were euthanized, along with 6 rats from the GNAL group. The medication was maintained, once a week, until euthanasia (thirteenth week) for the GAL group. The GZ group received Z four times a week, for four weeks, when the fourth week was completed, tooth extraction was performed, after which the 28-day period was awaited for the euthanasia of the animals in the respective group and another 6 in the GNZ group. The GDmab group received a total of 8 applications of Dmab, for a period of 4 weeks (2 weekly applications), when the fourth week was completed, the animals in the group underwent dental extraction and after 28 days were euthanized, together with the 6 remaining rats from the GNDmab group. The statistical analysis for qualitative variables was used Fisher's exact test, and for the analysis of quantitative variables, One-way ANOVA with Tukey's post hoc was used. Considering a significance level of 0.05. Our results demonstrated a higher prevalence of histological osteonecrosis in the group in the BFs when compared to the Denosumab group, as well as the decrease in the number of vessels was more frequent in the groups of the BFs. Thus, we conclude that, due to the decrease in angiogenesis and the increase in MRONJ in bone tissue, bisphosphonates have a greater alteration in the bone mechan
publishDate 2021
dc.date.accessioned.fl_str_mv 2021-06-18T17:31:47Z
dc.date.available.fl_str_mv 2021-06-18T17:31:47Z
dc.date.issued.fl_str_mv 2021-01-14
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/21150
url http://repositorio.ufsm.br/handle/1/21150
dc.language.iso.fl_str_mv por
language por
dc.relation.cnpq.fl_str_mv 400200000000
dc.relation.confidence.fl_str_mv 600
dc.relation.authority.fl_str_mv e4964e40-0663-4dd4-8f14-d62cdf602ede
1dc44013-ec57-4497-9b49-ad389c38a33b
04b974c8-cef0-437f-afa6-2a447a22eb9a
12cdec15-31d1-4e31-89fb-32ab2a72c1ba
019bd909-2c54-4eef-9485-76e2f1f9da0b
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Centro de Ciências da Saúde
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Ciências Odontológicas
dc.publisher.initials.fl_str_mv UFSM
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv Odontologia
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Centro de Ciências da Saúde
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
bitstream.url.fl_str_mv http://repositorio.ufsm.br/bitstream/1/21150/1/DIS_PPGCO_2021_SILVA_LUISA.pdf
http://repositorio.ufsm.br/bitstream/1/21150/3/license.txt
http://repositorio.ufsm.br/bitstream/1/21150/2/license_rdf
http://repositorio.ufsm.br/bitstream/1/21150/4/DIS_PPGCO_2021_SILVA_LUISA.pdf.txt
http://repositorio.ufsm.br/bitstream/1/21150/5/DIS_PPGCO_2021_SILVA_LUISA.pdf.jpg
bitstream.checksum.fl_str_mv cf2933f252a2562debb7193d949e1d88
2f0571ecee68693bd5cd3f17c1e075df
4460e5956bc1d1639be9ae6146a50347
0ca0b2bbb30480e3afe9f23f3de2af6b
3787fbfeb9d638aa33495c4a4676acf5
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv
_version_ 1801223943633240064